Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatitis A|Hepatitis C, Chronic
Phase 2: Hepatitis C, Chronic|Communicable Diseases|Hepatitis A|Hepatitis C
Phase 1: Hepatitis C, Chronic|Hepatitis A|Liver Failure|Hepatic Insufficiency|Hepatitis C
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01678131 |
MK-7009-048 | P1 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-08-27 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00954993 |
MK-7009-029 | P1 |
Terminated |
Hepatitis C, Chronic|Hepatitis A |
2011-03-04 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01010906 |
MK-7009-005 | P1 |
Completed |
Hepatitis C|Liver Failure|Hepatic Insufficiency |
2010-06-11 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00518622 |
NCT00518622 | P1 |
Completed |
Hepatitis C|Hepatitis A |
2008-09-01 |
2022-05-04 |
Primary Endpoints |
|
2009-013053-15 |
2009-013053-15 | P2 |
Completed |
Hepatitis C |
2013-05-29 |
2022-03-13 |
Treatments |
|
NCT00943761 |
MK-7009-028 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-05-29 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT00895882 |
NCT00895882 | P2 |
Withdrawn |
Hepatitis C, Chronic|Hepatitis A|Communicable Diseases |
2013-01-01 |
2022-05-04 |
Primary Endpoints |
|
2008-000150-12 |
2008-000150-12 | P2 |
Completed |
Hepatitis C, Chronic |
2012-09-10 |
2025-06-29 |
Treatments |
|
NCT00704405 |
MK-7009-009 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2012-03-26 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2009-012000-10 |
Safety, Tolerability, and Efficacy of MK-7009 study | P2 |
Terminated |
Hepatitis C, Chronic |
2010-09-08 |
2022-03-13 |
Treatments |
|
NCT00880763 |
NCT00880763 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2010-06-03 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2008-000149-72 |
2008-000149-72 | P2 |
Completed |
Hepatitis C, Chronic |
2010-04-14 |
2022-03-12 |
Treatments |
|
NCT00704184 |
MK-7009-007 | P2 |
Completed |
Hepatitis C |
2008-12-12 |
2022-05-04 |
Primary Endpoints |
|
NCT01370642 |
MK-7009-043 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-07-31 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01405560 |
MK-7009-045 | P3 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-03-29 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01405937 |
MK-7009-044 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-02-26 |
2022-05-04 |
Primary Endpoints|Treatments |